66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
Mark Sulkowski(Johns Hopkins University), Gerhard Steinmann(Boehringer Ingelheim (Germany)), Tarik Asselah(Inserm), S. Mauss(Center for HIV and Hepatogastroenterology), Florin Alexandru Căruntu(National Institute of Research and Development for Biological Sciences), Marc Bourlière(Universität Hamburg), Liliana Preoțescu(Virginia Commonwealth University), Dominique Larrey, Yakov Datsenko(Boehringer Ingelheim (Germany)), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Jean–Michel Pawlotsky(Université Paris-Est Créteil), Jerry O. Stern(Boehringer Ingelheim (United States)), Stanislas Pol(Université Paris Cité), Charles D. Hafner(Heidelberg University), J.‐P. Bronowicki(Délégation Centre-Est), Robert Kubiak(Boehringer Ingelheim (Germany)), W.O. Böcher(Boehringer Ingelheim (Germany)), Stephen D. Shafran(University of Alberta)
Cited by 30
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605